AAAAAA

   
Results: 1-7 |
Results: 7
IMPROVED SURVIVAL AND REDUCED CLINICAL PROGRESSION IN HIV-INFECTED PATIENTS WITH ADVANCED DISEASE TREATED WITH SAQUINAVIR PLUS ZALCITABINE
Authors: HAUBRICH R LALEZARI J FOLLANSBEE SE GILL MJ HIRSCH M RICHMAN D MILDVAN D BURGER HU BEATTIE D DONATACCI L SALGO MP
Citation: R. Haubrich et al., IMPROVED SURVIVAL AND REDUCED CLINICAL PROGRESSION IN HIV-INFECTED PATIENTS WITH ADVANCED DISEASE TREATED WITH SAQUINAVIR PLUS ZALCITABINE, Antiviral therapy, 3(1), 1998, pp. 33-42
TREATMENT OF CHILDREN WITH AUTISM - A RANDOMIZED CONTROLLED TRIAL TO EVALUATE A CAREGIVER-BASED INTERVENTION PROGRAM IN COMMUNITY DAY-CARE-CENTERS
Authors: JOCELYN LJ CASIRO OG BEATTIE D BOW J KNEISZ J
Citation: Lj. Jocelyn et al., TREATMENT OF CHILDREN WITH AUTISM - A RANDOMIZED CONTROLLED TRIAL TO EVALUATE A CAREGIVER-BASED INTERVENTION PROGRAM IN COMMUNITY DAY-CARE-CENTERS, Journal of developmental and behavioral pediatrics, 19(5), 1998, pp. 326-334
MECHANICAL ANALYSIS OF HETEROGENEOUS, ATHEROSCLEROTIC HUMAN AORTA
Authors: BEATTIE D XU G VITO R GLAGOV S WHANG WG
Citation: D. Beattie et al., MECHANICAL ANALYSIS OF HETEROGENEOUS, ATHEROSCLEROTIC HUMAN AORTA, Journal of biomechanical engineering, 120(5), 1998, pp. 602-607
YL-(S)-3-(2-NAPHTHYL)ALANYL-N-BENZYL-N-METHYLAMIDE (SDZ-NKT-343), A POTENT HUMAN NK1 TACHYKININ RECEPTOR ANTAGONIST WITH GOOD ORAL ANALGESIC ACTIVITY IN CHRONIC PAIN MODELS
Authors: WALPOLE C KO SY BROWN M BEATTIE D CAMPBELL E DICKENSON F EWAN S HUGHES GA LEMAIRE M LERPINIERE J PATEL S URBAN L
Citation: C. Walpole et al., YL-(S)-3-(2-NAPHTHYL)ALANYL-N-BENZYL-N-METHYLAMIDE (SDZ-NKT-343), A POTENT HUMAN NK1 TACHYKININ RECEPTOR ANTAGONIST WITH GOOD ORAL ANALGESIC ACTIVITY IN CHRONIC PAIN MODELS, Journal of medicinal chemistry, 41(17), 1998, pp. 3159-3173
INTEGRATED PROBLEM-BASED LEARNING FOR FIRST-YEAR MEDICAL-STUDENTS - DOES IT TEACH BIOCHEMICAL PRINCIPLES
Authors: HARRIS CL GUNER G ARBOGAST J SALATI L SHUMWAY JM CONNORS J BEATTIE D
Citation: Cl. Harris et al., INTEGRATED PROBLEM-BASED LEARNING FOR FIRST-YEAR MEDICAL-STUDENTS - DOES IT TEACH BIOCHEMICAL PRINCIPLES, The FASEB journal, 11(9), 1997, pp. 21-21
SAQUINAVIR PLUS ZALCITABINE VS SAQUINAVIR OR ZALCITABINE MONOTHERAPY IN HIV-INFECTED PATIENTS DISCONTINUING OR INTOLERANT TO ZIDOVUDINE - RESULTS OF A RANDOMIZED, DOUBLE-BLIND TRIAL
Authors: HAUBRICH R BURGER HU BEATTIE D DONATACCI L SALGO MP
Citation: R. Haubrich et al., SAQUINAVIR PLUS ZALCITABINE VS SAQUINAVIR OR ZALCITABINE MONOTHERAPY IN HIV-INFECTED PATIENTS DISCONTINUING OR INTOLERANT TO ZIDOVUDINE - RESULTS OF A RANDOMIZED, DOUBLE-BLIND TRIAL, AIDS, 10, 1996, pp. 81-81
EVOLUTION OF A NOVEL SERIES OF [(N,N-DIMETHYLAMINO)PROPYL]ANILIDE ANDPIPERAZINYLBENZANILIDES AS THE FIRST SELECTIVE 5-HT1D ANTAGONISTS
Authors: CLITHEROW JW SCOPES DIC SKINGLE M JORDAN CC FENIUK W CAMPBELL IB CARTER MC COLLINGTON EW CONNOR HE HIGGINS GA BEATTIE D KELLY HA MITCHELL WL OXFORD AW WADSWORTH AH TYERS MB
Citation: Jw. Clitherow et al., EVOLUTION OF A NOVEL SERIES OF [(N,N-DIMETHYLAMINO)PROPYL]ANILIDE ANDPIPERAZINYLBENZANILIDES AS THE FIRST SELECTIVE 5-HT1D ANTAGONISTS, Journal of medicinal chemistry, 37(15), 1994, pp. 2253-2257
Risultati: 1-7 |